February 8, 2016 4:02 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that on February 4, 2016, the Company attended a productive meeting with FDA reviewers and senior leaders to discuss resolution of issues identified during the enclomiphene NDA review. The meeting agenda covered a broad range of topics surrounding the NDA data as well as emerging Agency and expert thinking regarding the treatment of hypogonadism. The Company believes that it was clear during the meeting that the FDA is not closed to entertaining secondary hypogonadism as an indication.Conference Call Details:Time: Monday, February 8, 2016 – 5:00 PM EasternParticipant Dial-In Number (Domestic): 877-407-8629; International: 201-493-6715It is recommended that participants call in approximately 15 minutes prior to the start time of the conference call.Replay Call Details: Conference ID Number: 13595473Replay Dial-In (Toll Free): 877-660-6853Replay Dial-In (International): 201-612-7415Replay will be available through February 22, 2016.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.